- Home
- HMH vs OMER Comparison
HMH vs OMER Comparison
Compare HMH & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$20.36
HOLD
Current Price
$12.88
Company Overview
Basic Information| Metric | HMH | OMER |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil and Gas Field Machinery | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 873.0M | 844.6M |
| IPO Year | 2026 | 2008 |
Fundamental Metrics
Financial Performance| Metric | HMH | OMER |
|---|---|---|
| Price | $20.36 | $12.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 174.7K | ★ 1.4M |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.62 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $233.22 |
| P/E Ratio | ★ N/A | $20.18 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.80 | $3.70 |
| 52 Week High | $22.34 | $17.65 |
Technical Indicators
Market Signals| Indicator | HMH | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | N/A |
| Support Level | $18.39 | N/A |
| Resistance Level | $22.34 | N/A |
| Average True Range (ATR) | 1.17 | 0.00 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 50.92 | 0.00 |
Price Performance
Historical Comparison HMH
OMER
About OMER Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.